"This practice has been adopted by multiple organ-procurement organizations and is used on thousands of organ donors each year, without ever having been rigorously studied," one researcher said. 

The deal could also include additional clinical and regulatory milestone payments in the years ahead.

The research will focus on ways to improve the utilization of electronic resources among heart failure patients and the doctors who treat them.

Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.

The technology may not be cheap, but new research published in The American Journal of Cardiology suggests the investment is well worth it. 

GLP-1 agonists are often taken as daily or weekly injections. A new delivery system could help make it so those same drugs are only required three times per year. 

While TAVR and SAVR are reliable treatments for calcific aortic stenosis, some patients are not considered for those procedures due to severe comorbidities or a limited life expectancy. This is where the investigational Valvosoft device from Cardiawave enters the equation.

Medtronic acquired the technology behind the new device back in August.

The FDA considers this a Class I recall, which means using the impacted devices “may cause serious injuries or death.” One patient injury has been reported at this time. 

Following the popular Mediterranean diet instead of a “Western” diet can be quite beneficial for women in their forties and fifties, researchers confirmed.